CompuMed Inc. Launches CardioGramKids(tm) Parental Education Program to Help Mom...

CompuMed Inc. Launches CardioGramKids(tm) Parental Education Program to Help Mom
and Dad Identify At-Risk Kids Taking Psychotropic Drugs

LOS ANGELES, July 6, 2009 (GLOBE NEWSWIRE) -- CompuMed, Inc. (OTCBB:CMPD)
(www.compumed.net) today launched a parental information program for its
CardioGramKids(tm) Pediatric Screening Program. In tandem with pediatricians and
other healthcare providers nationally, CompuMed is providing electrocardiogram
(ECG) screening services to children and teenagers prior to prescribing or
taking psychotropic medications. The U.S. Food and Drug Administration (FDA)
issued a safety warning recently about stimulant medications in children which
referenced a possible association between the use of stimulant medications for
attention deficit hyperactivity disorder, known as ADHD, and sudden cardiac
death in healthy children. It referenced a study just published in the American
Journal of Psychiatry. The FDA also warned parents that they should not stop a
child's stimulant medication based on the study.

"Moms and Dads are not always aware of the potential side effects of certain
drugs," said Maurizio Vecchione, CompuMed's CEO. "That's why we are launching
this important parental education program. Children taking these medications are
at risk of developing serious or life threatening cardiac conditions and should
have ECG screenings prior to starting on these medications. We want parents to
ask important questions about pre-screening their kids, which could save
children's lives."

The American Heart Association and other leading groups have expressed concern
regarding reports of sudden deaths of children and adolescents treated with
psychotropic medications such as Ritalin(r), Adderall(r), Prozac(r), Paxil(r)
and others. Medical journals have long stated concerns regarding the
appropriateness of such therapy without taking suitable safeguards.

The FDA safety communication goes on to say, "That physicians follow the current
prescribing information (labeling) for these products, which recommends that
children, adolescents or adults who are being considered for treatment with ADHD
drug products work with their health care professional(s) to develop a treatment
plan that includes a careful health history for cardiovascular disease in the
child and his or her family. This includes performing a physical exam with
special focus on the cardiovascular system and consideration of further tests
such as a screening electrocardiogram and echocardiogram, if the history or
examination suggests underlying risk for or the presence of heart disease."

"We launched the CardioGramKids program six months ago in conjunction with a
renowned university and others are signing up for our program expressing
concerns about their pediatric patients and psychotropic drugs," said Mr.
Vecchione. "For this reason, we decided to launch the parent program even
earlier than planned because of the problems associated in children taking these
medications." He added that the new study suggests that doctors throughout the
country pay more attention to the risk factors of heart disease in children and
encourage parents to demand ECG screenings for any children who may be at risk.

Many specialties including pediatrics, primary care and psychiatry in the U.S.
are likely to see young patients who might need psychotropic drugs. A bill
likely to pass in Oregon will allow psychologists to prescribe them as well.
According to a 2008 report in Child and Adolescent Psychiatry and Mental Health,
approximately 6.7 percent of children in the U.S. are taking these medications
for emotional and behavioral problems like attention deficit hyperactivity
disorder, commonly referred to as ADHD. CompuMed's CardioGramKids will enable
physicians and psychologists to screen the children in their care.

For more information about CardioGramKids, contact CompuMed at 310-258-5000 or
www.compumed.net; CompuMed is on twitter @compumed.

About CompuMed

CompuMed, Inc. (OTCBB:CMPD) develops and markets products and services that
combine telemedicine, medical informatics and advanced imaging. The
CardioGram(tm) is one of the first telecommunication networks designed to
remotely interpret electrocardiograms and is used by private practice,
government and corporate healthcare providers nationwide. The OsteoGram(r) is a
noninvasive diagnostic system that provides effective and accurate bone density
measurement for screening for osteoporosis and assessing hip fracture risk. The
OsteoGram has significant cost advantages over other technologies in the
marketplace. The OsteoGram and CardioGram are cleared by the FDA and
reimbursable by Medicare. CompuMed distributes its products worldwide both
directly and through OEM partners. Visit CompuMed online at www.compumed.net.

Statements contained in this press release that are not historical facts, such
as statements about prospective earnings, savings, revenue, operations, revenue
and earnings growth, results of contracts and other financial results, are
forward-looking statements pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. All such forward-looking statements
including statements concerning the Company's plans, objectives, expectations
and intentions are based largely on management's expectations and are subject to
and qualified by risks and uncertainties that could cause actual results to
differ materially from those expressed or implied by such statements. These
statements are subject to uncertainties and risks including, without limitation,
competitive factors, outsourcing trends in the pharmaceutical industry, product
and service demand and acceptance, changes in technology, ability to raise
capital, the availability of appropriate acquisition candidates and/or business
partnerships, economic conditions, the impact of competition and pricing,
capacity and supply constraints or difficulties, government regulation and other
risks identified in the Company's filings with the Securities and Exchange
Commission including its Annual Report on Form 10-KSB and Quarterly Reports on
Form 10-QSB. All such forward-looking statements are expressly qualified by
these cautionary statements. The Company expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any forward-looking
statements to reflect events, conditions or circumstances on which any such
statement is based after the date hereof, except as required by law.

-0-
CONTACT: Tellem Worldwide Inc.
Susan Tellem, APR
310-313-3444
stellem@tellem.com